JP2017537611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537611A5 JP2017537611A5 JP2017522083A JP2017522083A JP2017537611A5 JP 2017537611 A5 JP2017537611 A5 JP 2017537611A5 JP 2017522083 A JP2017522083 A JP 2017522083A JP 2017522083 A JP2017522083 A JP 2017522083A JP 2017537611 A5 JP2017537611 A5 JP 2017537611A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- dna binding
- atr
- operably linked
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004568 DNA-binding Effects 0.000 claims description 131
- 108091033319 polynucleotide Proteins 0.000 claims description 61
- 102000040430 polynucleotide Human genes 0.000 claims description 61
- 239000002157 polynucleotide Substances 0.000 claims description 61
- 238000013518 transcription Methods 0.000 claims description 46
- 230000035897 transcription Effects 0.000 claims description 46
- 102100024811 DNA (cytosine-5)-methyltransferase 3-like Human genes 0.000 claims description 36
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 36
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 36
- 101000909250 Homo sapiens DNA (cytosine-5)-methyltransferase 3-like Proteins 0.000 claims description 36
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 claims description 33
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 claims description 33
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 claims description 33
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102100023696 Histone-lysine N-methyltransferase SETDB1 Human genes 0.000 claims description 28
- 101000684609 Homo sapiens Histone-lysine N-methyltransferase SETDB1 Proteins 0.000 claims description 28
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000012636 effector Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 108091006107 transcriptional repressors Proteins 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 108091033409 CRISPR Proteins 0.000 claims description 9
- 238000010354 CRISPR gene editing Methods 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 8
- 102100025169 Max-binding protein MNT Human genes 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 101150061166 tetR gene Proteins 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 238000001415 gene therapy Methods 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 230000030279 gene silencing Effects 0.000 claims description 3
- 230000010474 transient expression Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021213691A JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2025005873A JP2025063201A (ja) | 2014-10-24 | 2025-01-16 | 持続的エピジェネティック遺伝子サイレンシング |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1418965.8A GB201418965D0 (enExample) | 2014-10-24 | 2014-10-24 | |
| GB1418965.8 | 2014-10-24 | ||
| PCT/IB2015/058202 WO2016063264A1 (en) | 2014-10-24 | 2015-10-23 | Permanent epigenetic gene silencing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021213691A Division JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537611A JP2017537611A (ja) | 2017-12-21 |
| JP2017537611A5 true JP2017537611A5 (enExample) | 2018-12-06 |
| JP7002936B2 JP7002936B2 (ja) | 2022-02-04 |
Family
ID=52103358
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522083A Active JP7002936B2 (ja) | 2014-10-24 | 2015-10-23 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2021213691A Active JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2025005873A Pending JP2025063201A (ja) | 2014-10-24 | 2025-01-16 | 持続的エピジェネティック遺伝子サイレンシング |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021213691A Active JP7623272B2 (ja) | 2014-10-24 | 2021-12-28 | 持続的エピジェネティック遺伝子サイレンシング |
| JP2025005873A Pending JP2025063201A (ja) | 2014-10-24 | 2025-01-16 | 持続的エピジェネティック遺伝子サイレンシング |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12152240B2 (enExample) |
| EP (2) | EP3209783B1 (enExample) |
| JP (3) | JP7002936B2 (enExample) |
| CN (2) | CN116789846A (enExample) |
| AU (3) | AU2015334469B2 (enExample) |
| CA (1) | CA2965591A1 (enExample) |
| DK (1) | DK3209783T3 (enExample) |
| ES (1) | ES2906263T3 (enExample) |
| GB (1) | GB201418965D0 (enExample) |
| HU (1) | HUE057846T2 (enExample) |
| PL (1) | PL3209783T3 (enExample) |
| PT (1) | PT3209783T (enExample) |
| WO (1) | WO2016063264A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| GB201418965D0 (enExample) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| WO2016073955A2 (en) * | 2014-11-06 | 2016-05-12 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| EP3256487A4 (en) | 2015-02-09 | 2018-07-18 | Duke University | Compositions and methods for epigenome editing |
| EP3273976B1 (en) * | 2015-03-27 | 2023-07-26 | President and Fellows of Harvard College | Modified t cells and methods of making and using the same |
| US11674144B2 (en) * | 2015-04-16 | 2023-06-13 | California Institute Of Technology | Fractional regulation of transcription |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| CN108779466B (zh) | 2015-11-30 | 2024-03-29 | 杜克大学 | 用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法 |
| CA3006432A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| EP3463484B1 (en) * | 2016-05-27 | 2026-01-07 | The Regents of the University of California | Methods and compositions for targeting rna polymerases and non-coding rna biogenesis to specific loci |
| WO2017208247A1 (en) * | 2016-06-02 | 2017-12-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
| WO2018017754A1 (en) | 2016-07-19 | 2018-01-25 | Duke University | Therapeutic applications of cpf1-based genome editing |
| CA3034369A1 (en) | 2016-08-19 | 2018-02-22 | Whitehead Institute For Biomedical Research | Methods of editing dna methylation |
| WO2018049079A1 (en) | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| EP3551218A4 (en) * | 2016-12-12 | 2020-12-09 | Whitehead Institute for Biomedical Research | REGULATION OF TRANSCRIPTION THANKS TO CTCF LOOP ANCHORS |
| FI3565891T3 (fi) | 2017-01-09 | 2023-07-04 | Whitehead Inst Biomedical Res | Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä |
| WO2018160908A1 (en) * | 2017-03-03 | 2018-09-07 | Flagship Pioneering, Inc. | Methods and systems for modifying dna |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| AU2018367896B2 (en) | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11072782B2 (en) | 2017-07-24 | 2021-07-27 | Albert-Ludwigs-Universitaet Freiburg | Construct for epigenetic modification and its use in the silencing of genes |
| CN107759673B (zh) * | 2017-09-27 | 2021-06-04 | 复旦大学 | 可对hbv的dna进行表观甲基化修饰的蛋白分子及其应用 |
| US11629342B2 (en) | 2017-10-17 | 2023-04-18 | President And Fellows Of Harvard College | Cas9-based transcription modulation systems |
| EP3740580A4 (en) | 2018-01-19 | 2021-10-20 | Duke University | GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS |
| JP7555822B2 (ja) * | 2018-04-19 | 2024-09-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | ゲノム編集のための組成物および方法 |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| US20220017926A1 (en) * | 2018-09-21 | 2022-01-20 | Cafa Therapeutics Limited | Method for gene editing of cell on the basis of crispr/cas system |
| GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| US12428639B2 (en) | 2019-03-05 | 2025-09-30 | Ramot At Tel-Aviv University Ltd. | Plant DNA methyltransferases and uses thereof |
| JP7618581B2 (ja) | 2019-04-23 | 2025-01-21 | サンガモ セラピューティクス， インコーポレイテッド | ９番染色体オープンリーディングフレーム７２遺伝子発現のモジュレーターおよびその使用 |
| EP3962535A1 (en) | 2019-04-30 | 2022-03-09 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| AU2020352552A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
| JP2023501617A (ja) * | 2019-11-13 | 2023-01-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Ｃａｒ－ｔ細胞を製造する方法 |
| US20210139850A1 (en) * | 2019-11-13 | 2021-05-13 | Crispr Therapeutics Ag | Manufacturing process for making t cells expressing chimeric antigen receptors |
| EP4217477A4 (en) * | 2020-09-24 | 2024-10-16 | Flagship Pioneering Innovations V, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION |
| AU2021409729A1 (en) * | 2020-12-22 | 2023-07-13 | Nchroma Bio, Inc. | Compositions and methods for epigenetic editing |
| EP4284932A1 (en) * | 2021-02-01 | 2023-12-06 | Epsilen Bio S.r.l. | Gene silencing |
| JP2024506208A (ja) * | 2021-02-15 | 2024-02-09 | オスペダーレ サン ラファエレ エス．アール．エル | 癌の治療のためのエピジェネティックサイレンシング |
| CN115247175B (zh) * | 2021-11-25 | 2025-10-17 | 南京启真基因工程有限公司 | 构建setdb1基因突变的表观遗传失调模型猪核移植供体细胞的基因编辑系统及其应用 |
| WO2023165597A1 (en) * | 2022-03-04 | 2023-09-07 | Epigenic Therapeutics , Inc. | Compositions and methods of genome editing |
| EP4544057A1 (en) * | 2022-06-23 | 2025-04-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of trac expression |
| JP2025525389A (ja) * | 2022-06-23 | 2025-08-05 | エヌクロマ・バイオ，インコーポレーテッド | Ｃｉｉｔａ発現のエピジェネティック調節のための組成物及び方法 |
| JP2025521581A (ja) * | 2022-06-23 | 2025-07-10 | エヌクロマ・バイオ，インコーポレーテッド | エピジェネティック編集用の組成物および方法 |
| CA3260474A1 (en) * | 2022-06-23 | 2023-12-28 | Chroma Medicine, Inc. | COMPOSITIONS AND METHODS OF EPIGENETIC REGULATION OF B2M EXPRESSION |
| AU2023289696A1 (en) | 2022-06-24 | 2025-01-16 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
| IL318767A (en) | 2022-08-19 | 2025-04-01 | Tune Therapeutics Inc | Compounds, systems and methods for regulating hepatitis B virus through targeted gene repression |
| JP2025532177A (ja) * | 2022-09-23 | 2025-09-29 | エヌクロマ・バイオ，インコーポレーテッド | Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法 |
| WO2024081879A1 (en) * | 2022-10-14 | 2024-04-18 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of cd247 expression |
| KR20250165443A (ko) | 2023-02-17 | 2025-11-25 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | 후성유전학적 변형 제조를 위한 조성물 및 방법 |
| WO2024220857A1 (en) * | 2023-04-20 | 2024-10-24 | Chroma Medicine, Inc. | Fusion proteins for epigenetic regulation |
| WO2024238700A1 (en) * | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| IT202300011790A1 (it) | 2023-06-08 | 2024-12-08 | Fond Telethon Ets | Protocolli di manipolazione genica in cellule immunitarie |
| WO2025031446A1 (zh) * | 2023-08-09 | 2025-02-13 | 厦门大学 | 瓜氨酸化setdb1多肽及其在诊断类风湿性关节炎中的应用 |
| WO2025160155A1 (en) | 2024-01-22 | 2025-07-31 | The Broad Institute, Inc. | Epigenetic targeting of prion diseases |
| WO2025261473A1 (zh) * | 2024-06-21 | 2025-12-26 | 益杰立科(上海)生物科技有限公司 | 工程化基因转录阻抑工具及其用途 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| KR20000029858A (ko) | 1996-08-07 | 2000-05-25 | 마르크 젠너 | 엠엠피와티엔에프억제활성을갖는히드록삼산및카르복실산유도체 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US20020188103A1 (en) | 1998-10-09 | 2002-12-12 | Timothy H. Bestor | Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| EP1276859B1 (en) * | 2000-04-28 | 2007-02-07 | Sangamo Biosciences Inc. | Targeted modification of chromatin structure |
| US6919204B2 (en) | 2000-09-29 | 2005-07-19 | Sangamo Biosciences, Inc. | Modulation of gene expression using localization domains |
| WO2003072788A1 (en) | 2002-02-21 | 2003-09-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for reversibly controlling expression of target genes in cells |
| WO2005028630A2 (en) | 2003-09-19 | 2005-03-31 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for regulation of gene expression |
| US20070192880A1 (en) | 2003-10-03 | 2007-08-16 | University Of Rochester | Horming response element binding transregulators |
| AU2005233550B2 (en) | 2004-04-08 | 2010-11-18 | Sangamo Therapeutics, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| GB0526449D0 (en) | 2005-12-23 | 2006-02-08 | Medical Res Council | Polypeptide targeting |
| KR100756055B1 (ko) | 2006-01-27 | 2007-09-07 | 연세대학교 산학협력단 | 신생혈관 생성을 조절하는 재조합 아데노바이러스 |
| GB0607063D0 (en) | 2006-04-07 | 2006-05-17 | Cellcentric Ltd | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
| GB0700374D0 (en) | 2007-01-09 | 2007-02-14 | Oncomethylome Sciences S A | NDRG family methylation markers |
| US20120207744A1 (en) | 2009-03-19 | 2012-08-16 | Mendlein John D | Reprogramming compositions and methods of using the same |
| CA2769262C (en) | 2009-07-28 | 2019-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| GB201121924D0 (en) | 2011-12-20 | 2012-02-01 | Fahy Gurteen Labs Ltd | Detection of breast cancer |
| EP2820127B1 (en) | 2012-02-28 | 2018-09-26 | Sigma Aldrich Co. LLC | Targeted histone acetylation |
| MX374399B (es) | 2012-02-29 | 2025-03-06 | Sangamo Biosciences Inc | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. |
| CN107267554A (zh) | 2012-03-14 | 2017-10-20 | 萨克生物研究学院 | 腺病毒肿瘤诊断法 |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| EP4570908A3 (en) | 2012-05-25 | 2025-10-22 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| CN116064532A (zh) | 2012-10-23 | 2023-05-05 | 基因工具股份有限公司 | 用于切割靶dna的组合物及其用途 |
| SG11201503824SA (en) | 2012-12-06 | 2015-06-29 | Sigma Aldrich Co Llc | Crispr-based genome modification and regulation |
| WO2014093595A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| PT2784162E (pt) | 2012-12-12 | 2015-08-27 | Broad Inst Inc | Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências |
| DK3064585T3 (da) | 2012-12-12 | 2020-04-27 | Broad Inst Inc | Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| KR102405549B1 (ko) | 2013-03-15 | 2022-06-08 | 더 제너럴 하스피탈 코포레이션 | Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용 |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| US20140356956A1 (en) | 2013-06-04 | 2014-12-04 | President And Fellows Of Harvard College | RNA-Guided Transcriptional Regulation |
| JP7085716B2 (ja) | 2013-06-05 | 2022-06-17 | デューク ユニバーシティ | Ｒｎａガイド遺伝子編集及び遺伝子調節 |
| WO2015006294A2 (en) | 2013-07-10 | 2015-01-15 | President And Fellows Of Harvard College | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150191744A1 (en) | 2013-12-17 | 2015-07-09 | University Of Massachusetts | Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling |
| CA2942915A1 (en) | 2014-03-20 | 2015-09-24 | Universite Laval | Crispr-based methods and products for increasing frataxin levels and uses thereof |
| WO2016011080A2 (en) | 2014-07-14 | 2016-01-21 | The Regents Of The University Of California | Crispr/cas transcriptional modulation |
| CA2954920A1 (en) | 2014-07-14 | 2016-01-21 | The Regents Of The University Of California | A protein tagging system for in vivo single molecule imaging and control of gene transcription |
| US20170233762A1 (en) | 2014-09-29 | 2017-08-17 | The Regents Of The University Of California | Scaffold rnas |
| CN107530399B (zh) | 2014-10-10 | 2022-03-18 | 马萨诸塞眼科耳科诊所 | 治疗分子在体外和体内的有效递送 |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| LT3250691T (lt) | 2015-01-28 | 2023-09-11 | Caribou Biosciences, Inc. | Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai |
| EP3256487A4 (en) | 2015-02-09 | 2018-07-18 | Duke University | Compositions and methods for epigenome editing |
| EP3325018B1 (en) | 2015-07-22 | 2025-01-15 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
| HK1257460A1 (zh) | 2015-09-09 | 2019-10-18 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 用於免疫疗法的巨噬细胞的遗传工程 |
| EP3147363B1 (en) | 2015-09-26 | 2019-10-16 | B.R.A.I.N. Ag | Activation of taste receptor genes in mammalian cells using crispr-cas-9 |
| US10612044B2 (en) | 2015-11-25 | 2020-04-07 | National University Corporation Gunma University | DNA methylation editing kit and DNA methylation editing method |
-
2014
- 2014-10-24 GB GBGB1418965.8A patent/GB201418965D0/en not_active Ceased
-
2015
- 2015-10-23 CA CA2965591A patent/CA2965591A1/en active Pending
- 2015-10-23 PL PL15794644T patent/PL3209783T3/pl unknown
- 2015-10-23 CN CN202211663401.6A patent/CN116789846A/zh active Pending
- 2015-10-23 HU HUE15794644A patent/HUE057846T2/hu unknown
- 2015-10-23 EP EP15794644.3A patent/EP3209783B1/en active Active
- 2015-10-23 WO PCT/IB2015/058202 patent/WO2016063264A1/en not_active Ceased
- 2015-10-23 CN CN201580057762.8A patent/CN107109433B/zh active Active
- 2015-10-23 EP EP21197502.4A patent/EP3995584A1/en active Pending
- 2015-10-23 PT PT157946443T patent/PT3209783T/pt unknown
- 2015-10-23 ES ES15794644T patent/ES2906263T3/es active Active
- 2015-10-23 DK DK15794644.3T patent/DK3209783T3/da active
- 2015-10-23 AU AU2015334469A patent/AU2015334469B2/en active Active
- 2015-10-23 US US15/521,294 patent/US12152240B2/en active Active
- 2015-10-23 JP JP2017522083A patent/JP7002936B2/ja active Active
-
2021
- 2021-12-28 JP JP2021213691A patent/JP7623272B2/ja active Active
-
2022
- 2022-04-12 AU AU2022202407A patent/AU2022202407B2/en active Active
-
2025
- 2025-01-16 JP JP2025005873A patent/JP2025063201A/ja active Pending
- 2025-02-13 AU AU2025201007A patent/AU2025201007A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537611A5 (enExample) | ||
| JP7553110B2 (ja) | エピゲノム編集のための組成物および方法 | |
| JP7395483B2 (ja) | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 | |
| CA3202977A1 (en) | Compositions and methods for epigenetic editing | |
| CN109640946A (zh) | 通过基因编辑策略进行hiv-1的负反馈调节 | |
| JP2017525336A5 (enExample) | ||
| BR112019020001A2 (pt) | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais | |
| JP2017524337A5 (enExample) | ||
| FI3988656T3 (fi) | Nukleosomien kanssa vuorovaikutteisten proteiinidomeenien käyttö tehostamaan kohdennettua genomimodifikaatiota | |
| CN116064678A (zh) | 用于活化γ-δT细胞的方法和组合物 | |
| BR112021009379A2 (pt) | anelossomos para entrega de modalidades terapêuticas secretadas | |
| EP3483275B1 (en) | Adipocyte-targeting non-viral gene delivery complex comprising dual plasmid vector | |
| JP2017006120A5 (enExample) | ||
| JP2018528237A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| JP2017529326A5 (enExample) | ||
| WO2020127532A3 (en) | Rna encoding a protein | |
| JP2015529454A5 (enExample) | ||
| US20210369810A1 (en) | Self-replicating cell selective gene delivery compositions, methods, and uses thereof | |
| Ishikawa et al. | Phage ϕC31 integrase‐mediated genomic integration of the common cytokine receptor gamma chain in human T‐cell lines | |
| CN110684841A (zh) | let-7b和rSjp40在制备预防或治疗血吸虫感染肝纤维化药物方面的应用 | |
| CN111574611B (zh) | 一种促进stat3活化的人源蛋白及其药物应用 | |
| JP2022502081A (ja) | 遺伝子操作された微生物ならびにそれを作製および使用する方法 | |
| Boroujeni et al. | Induction of Apoptosis and Autophagy Using Ectopic DSCR1 Expression in Breast Cancer Cells. | |
| WO2021218802A1 (zh) | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |